See more : Rock Edge Resources Ltd. (REDG.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Q32 Bio Inc. (QTTB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Q32 Bio Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Compañía Minera Autlán, S.A.B. de C.V. (AUTLANB.MX) Income Statement Analysis – Financial Results
- DCX Systems Limited (DCXINDIA.NS) Income Statement Analysis – Financial Results
- China Resources Cement Holdings Limited (CARCY) Income Statement Analysis – Financial Results
- Kilroy Realty Corporation (KRC) Income Statement Analysis – Financial Results
- Wells Fargo & Company (WFC-PA) Income Statement Analysis – Financial Results
Q32 Bio Inc. (QTTB)
Industry: Biotechnology
Sector: Healthcare
About Q32 Bio Inc.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.16M | 6.65M | 33.97M | 2.70M | 1.67M | 5.32M | 0.00 | 0.00 |
| Cost of Revenue | 578.00K | 2.60M | 9.54M | 0.00 | 0.00 | 0.00 | 684.21K | 239.80K |
| Gross Profit | 578.00K | 4.05M | 24.43M | 2.70M | 1.67M | 5.32M | -684.21K | -239.80K |
| Gross Profit Ratio | 50.00% | 60.92% | 71.91% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 62.00M | 35.81M | 29.93M | 100.39M | 89.40M | 47.95M | 21.38M | 5.69M |
| General & Administrative | 0.00 | 10.06M | 6.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.68M | 10.06M | 6.76M | 23.67M | 15.89M | 16.01M | 7.60M | 4.07M |
| Other Expenses | 0.00 | -1.12M | -324.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 92.68M | 45.88M | 36.69M | 124.06M | 105.29M | 63.96M | 28.97M | 9.76M |
| Cost & Expenses | 93.26M | 45.88M | 36.69M | 132.97M | 111.61M | 65.25M | 29.66M | 10.00M |
| Interest Income | 5.58M | 0.00 | 0.00 | 1.57M | 6.03M | 4.35M | 542.64K | 24.20K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 578.00K | 2.60M | 9.54M | 8.90M | 6.32M | 1.29M | 684.21K | 239.80K |
| EBITDA | -86.50M | -38.86M | -86.22M | -121.36M | -103.63M | -58.64M | -29.31M | -7.81M |
| EBITDA Ratio | -7,482.87% | -548.08% | -107.87% | -4,491.45% | -6,219.99% | -1,101.79% | 0.00% | 0.00% |
| Operating Income | -92.10M | -39.23M | -36.69M | -130.26M | -109.94M | -59.93M | -29.66M | -10.00M |
| Operating Income Ratio | -7,967.30% | -589.76% | -108.01% | -4,820.98% | -6,599.22% | -1,126.01% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.02M | -3.52M | -324.00K | 1.57M | 6.03M | 4.35M | -333.37K | 1.95M |
| Income Before Tax | -87.08M | -42.75M | -37.02M | -128.69M | -103.92M | -55.58M | -29.99M | -8.05M |
| Income Before Tax Ratio | -7,532.87% | -642.72% | -108.97% | -4,762.92% | -6,237.45% | -1,044.29% | 0.00% | 0.00% |
| Income Tax Expense | 25.88M | 62.00K | 547.00K | -1.00 | 0.00 | 0.00 | -4.00 | 2.00 |
| Net Income | -112.96M | -42.81M | -37.56M | -128.69M | -103.92M | -55.58M | -29.99M | -8.05M |
| Net Income Ratio | -9,771.71% | -643.65% | -110.58% | -4,762.92% | -6,237.45% | -1,044.29% | 0.00% | 0.00% |
| EPS | -35.16 | -13.42 | -12.23 | -50.46 | -44.41 | -35.04 | -14.42 | -3.87 |
| EPS Diluted | -35.16 | -13.42 | -12.23 | -50.46 | -44.41 | -35.04 | -14.42 | -3.87 |
| Weighted Avg Shares Out | 3.21M | 3.19M | 3.07M | 2.55M | 2.34M | 1.59M | 2.08M | 2.08M |
| Weighted Avg Shares Out (Dil) | 3.21M | 3.19M | 3.07M | 2.55M | 2.34M | 1.59M | 2.08M | 2.08M |
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
-- Bempikibart Phase 2 topline results in atopic dermatitis (AD) and alopecia areata (AA) remain on-track for Q4'24, with topline data from both trials expected in December -- -- Enrollment ongoing in ADX-097 Phase 2 basket trial for complement mediated...
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
WALTHAM, Mass. , Nov. 5, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in a fireside chat at...
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024
-- Poster presentation to highlight data from completed first-in-human, Phase 1 ascending dose clinical trial of ADX-097 in healthy volunteers; results support Phase 2 dose selection and continued clinical advancement of ADX-097 -- WALTHAM, Mass. , Oct. 14, 2024 /PRNewswire/...
Q32 Bio to Participate in Upcoming September Investor Conferences
WALTHAM, Mass. , Aug. 29, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in three upcoming investor conferences...
Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097
Q32 Bio's Bempikibart and ADX-097 are in Phase 2 trials, targeting autoimmune and inflammatory diseases, with significant potential to address unmet medical needs. The company's unique approach of localized inhibition minimizes side effects and enhances efficacy, differentiating it in the...
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 91.69%: Read This Before Placing a Bet
The consensus price target hints at a 91.7% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an...
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis
-- Exceeded enrollment target due to patient demand; trial size increased to 121 patients -- -- Bempikibart topline results remain on track to be released in Q4'24 -- WALTHAM, Mass. , July 9, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:...
Q32 Bio Joins Russell 3000® Index
WALTHAM, Mass. , July 1, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that the company is joining the broad-market Russell 3000®...
Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
-- Completed enrollment in bempikibart alopecia areata (AA) Phase 2 clinical trial, with topline results expected in Q4'24; enrollment in bempikibart atopic dermatitis (AD) Phase 2 clinical trial remains on-track, with topline results expected in Q4'24 -- -- ADX-097 continues...
Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer
WALTHAM, Mass. , April 3, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Lee Kalowski as President and Chief Financial...
Source: https://incomestatements.info
Category: Stock Reports